ARWR

NASDAQ · Biotechnology

Arrowhead Pharmaceuticals In

Mid-Cap Stocks Biotech Stocks Healthcare Stocks

$58.16

+0.70 (+1.22%)

As of Nov 7, 1:18 AM ET ·

ARWR News2 articles

Arrowhead Surges 23% on Positive Plozasiran Phase 3 Data

Arrowhead Pharmaceuticals (ARWR) shares surged 23% after Plozasiran Phase 3 data showed 79-81% median triglyceride reduction and 78% fewer pancreatitis events.

Arrowhead Sees Volatility After S&P MidCap 400 Inclusion, Goldman Eyes 2026 Pipeline

Arrowhead Pharmaceuticals shares experienced heightened trading activity and a slight decline following its transition to the S&P MidCap 400 index. Goldman Sachs reiterated a Neutral stance, highlighting pivotal 2026 clinical data and competitive pressures.